SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is generating strong community buzz as its AI-powered ecosystem expands with new exchange listings and cross-chain integrations, leading many to anticipate significant price milestones and further utility growth.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending following a drastic stock plunge driven by the abrupt departure of its CFO and general counsel, an SEC investigation into cash management, and an accounting review exposing internal control weaknesses and revised future guidance, sparking intense community debate between those foreseeing catastrophe and others viewing it as an extreme overreaction and buying opportunity.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is soaring after pre-announcing preliminary Q3 revenue well above expectations and reiterating robust fiscal year growth, fueling strong community belief that the AI data center infrastructure play was significantly undervalued amid massive hyperscaler capital expenditure. Traders are actively discussing the stock's sharp rebound and its potential for continued upside as a key beneficiary of the ongoing AI buildout.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is seeing significant conversation after its CEO signaled multi-year highs in mortgage loan production and gain-on-sale performance, leading to community debate on whether its integrated platform can overcome broader housing market headwinds amidst ongoing institutional accumulation.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Satellos Bioscience Inc

MSLE is actively discussed following its recent NASDAQ listing, a reverse split, and a substantial equity raise. While optimists view the financing as a strong vote of confidence in its "revolutionary" muscle regeneration drug for Duchenne patients and foresee potential acquisition, skeptics caution about dilution and characterize early clinical data as premature hype.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively discussed as the community awaits crucial R2 SUV details and earnings, with its CEO emphasizing the R2's cost-efficient design and potential to significantly boost profitability, though investor sentiment remains divided on its market impact and the company's cash burn amid EV sector competition.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is a top trending stock as investors keenly await its earnings report tomorrow, with significant community speculation around a potential beat and strong guidance. Many perceive the cloud observability leader as an undervalued AI beneficiary after recent sector-wide pressures, driving discussions of a major buying opportunity.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is trending following the FDA's issuance of a Complete Response Letter for its Hunter syndrome gene therapy, RGX-121, citing concerns with trial design and the appropriateness of its surrogate endpoint. The community is actively debating the broader implications for gene therapies, RGNX's financial outlook, and potential impacts on its Duchenne and AbbVie-partnered programs.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending as its stock experiences a steep decline despite a recent Q4 earnings beat, prompting community concern over executive stock-based compensation and competitive pressures from rivals developing similar app features.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is trending as its highly dedicated community champions a "permissionless brand" model, consistently launching real-world products like KENDU SPICE, fostering strong conviction and active accumulation even amidst broader market downturns. This unique approach to building real value differentiates it as a long-term play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund lifted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 86.4% in the third quarter, according to the company in its most...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Cross Above 50-Day Moving Average - Here's Why

Amphastar Pharmaceuticals (NASDAQ:AMPH) Share Price Passes Above 50-Day Moving Average - What's Next...

CRMD Down 31% in a Month: Is This an Indication to Sell the Stock?

CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, likely souring investor sentiment.

Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption?

CorMedix's DefenCath drives revenues with strong adoption, but 2026 outlook signals slower growth, raising concerns over long-term adoption.

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Hold" from Analysts

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) has been assigned an average recommendation of "Hold" from the eight ratings firms that are currently covering the company, Marketbeat...

Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings?

CRMD's DefenCath, the only FDA-approved antimicrobial catheter lock, saw higher outpatient dialysis use in the fourth quarter, likely driving revenues.

Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth

Amphastar Pharmaceuticals (NASDAQ:AMPH) executives used a conference presentation to highlight the company's shift toward higher-value proprietary products, while also outlining near-term launch...

Amphastar Pharmaceuticals, Inc. $AMPH Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 98.2% during the third quarter, according to the company in its most recent 13F filing with...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) has earned a consensus recommendation of "Hold" from the eight research firms that are presently covering the company, MarketBeat.com...

129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to the company in its most recent disclosure...

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Amphastar Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.93	--	--	N/A
Q3 '25	$0.83	$0.93	12.68%	BEAT
Q2 '25	$0.74	$0.85	14.61%	BEAT
Q1 '25	$0.69	$0.74	7.77%	BEAT
Q4 '24	$0.94	$0.92	-1.95%	MISSED

AMPH
Amphastar Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest AMPH News

AMPHAmphastar Pharmaceuticals Inc